Clinical characteristics of the double primary malignant tumors of uterine corpus/breast

doi:10.3969/j.issn.1006-7795.2019.06.010

Abstract

Abstract: Objective To investigate the clinical and pathological characteristics of the double primary malignant tumors of uterine corpus/breast. Methods A case-control study was performed for the clinical and pathological data of 29 patients with primary malignant uterine tumor and breast cancer (double cancers group) and 319 patients with only endometrial malignancy (single cancer group) who had visited Beijing Chaoyang Hospital during January 2004 to January 2015. Results Double cancers group showed a significantly higher percentage of patients with diabetes(χ²=8.02,P=0.007),family history of cancer(χ²=31.76,P<0.001),with other primary tumor(χ²=31.76,P<0.001),and type Ⅱ endometrial carcinoma(χ²=5.52,P=0.030) and poorly-differentiated cancer tissue (χ²=8.39,P=0.02)compared with endometrial malignant group. Endometrial cancer group had a significantly better overall survival compared with double cancers group (Log-rank=6.75,P=0.011). Stratified analysis showed that the group of double cancers with primary endometrial malignancy showed a significantly higher percentage of patients with type Ⅱ endometrial carcinoma (58.33% vs 11.76%) than that with primary breast cancer, with a significantly shorter interval between the two tumors (t=2.23,P=0.028). Conclusion The clinical and pathological characteristics of endometrial malignancy with primary breast cancer is different from that of only endometrial malignancy. The clinical and pathological characteristics of breast cancer with primary malignant uterine tumor is different from that of endometrial malignant with primary breast cancer.

Key words: endometrial malignant, breast cancer, survival analysis, prognosis

CLC Number:

R737.3

Wang Wei, Zhang Zihan, Zhai Yan, Sang Cuiqin, Wang Shuzhen. Clinical characteristics of the double primary malignant tumors of uterine corpus/breast[J]. Journal of Capital Medical University, 2019, 40(6): 857-862.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.06.010

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I6/857

References

[1] 黄育北, 佟仲生, 陈可欣, 等. 《中国女性乳腺癌筛查指南》解读(精简版)[J]. 中国肿瘤临床, 2019,46(9):432-440.
[2] Grzankowski K S, Szender J B, Spring-Robinson C L, et al. Evaluation of metachronous breast and endometrial cancers before and after routine adjuvant tamoxifen usage[J]. Gynecol Oncol, 2016, 141(1):129-130.
[3] Warren S,Gates O. Multiple primary malignant tumors. A survey of the literature and a statistical study[J]. Am J Cancer 1932,16:1358-1414.
[4] Shinohara M,Matsuura Y,Baba S,et al. Multiple primary cancers associated with gynecologic malignancies[J]. Nihon Sanka Fujinka Gakkai Zasshi,1990,42(6):561-566.
[5] Petrucci M S,Bianconi F,Dolciami F,et al. Multiple primary cancers in women with gynaecological malignancies:a cancer registry-based study in Umbria region of Italy[J]. Eur J Gynaecol Oncol,2014,35(6):631-634.
[6] Schonfeld S J,De Gonzalez A B,Visvanathan K,et al. Declining second primary ovarian cancer after first primary breast cancer[J]. J Clin Oncol,2013,31(6):738-743.
[7] Siegel R L,Miller K D,Jemal A. Cancer statistics,2019[J]. CA Cancer J Clin,2019,69(1):7-34.
[8] Molina-Montes E,Requena M,Sánchez-Cantalejo E,et al. Risk of second cancers cancer after a first primary breast cancer:a systematic review and meta-analysis[J]. Gynecol Oncol,2015,136(1):158-171.
[9] Shu C A,Pike M C,Jotwani A R,et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations[J]. JAMA Oncol,2016,2(11):1434-1440.
[10] Nair N,Schwartz M,Guzzardi L,et al. Hysterectomy at the time of risk-reducing surgery in BRCA carriers[J]. Gynecol Oncol Rep,2018,26:71-74.
[11] Long B,Lilyquist J,Weaver A,et al. Cancer susceptibility gene mutations in type I and Ⅱ endometrial cancer[J]. Gynecol Oncol,2019,152(1):20-25.
[12] Bani-Mostafavi E S,Tayebi S,Tayebi M,et al. Case report:synchronous primary malignancy including the breast and endometrium[J]. Version 3 F1000Res,2017,6:1502.
[13] Ngô C,Brugier C,Plancher C,et al. Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer,with or without tamoxifen:A comparative study in 363 patients[J]. Eur J Surg Oncol,2014,40(10):1237-1244.
[14] Matsuo K, Mandelbaum R S, Machida H,et al. Decreasing secondary primary uterine cancer after breast cancer:A population-based analysis[J]. Gynecol Oncol,2019,154:169-176.
[15] 刘晨,刘军,王淑珍,等.乳腺癌术后并发妇科生殖道恶性肿瘤的高危因素分析[J].首都医科大学学报,2017,38(1):92-96.
[16] Garg K,Karnezis A N,Rabban J T. Uncommon hereditary gynaecological tumour syndromes:Pathological features in tumours that may predict risk for a germline mutation[J]. Pathology,2018,50(2):238-256.
[17] Zhang J, Li L, Lu Y. Suppression of hypoxia/HIF-1° promoted breast cancer malignant progression by p16/INK4a[J].Mol Ther,2014,22:169.
[18] Kim H Y, Ha Thi H T,Suntaek Hongg. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor[J].Cancer Lett,2018,415:30-39.
[19] Samanta S,Guru S, Elaimy A L,et al. Mercurio.IMP3 stabilization of WNT5B mRNA facilitates TAZ activation in breast cancer[J].Cell Rep,2018,23(9):2559-2567.